Table 2.

Unadjusted and adjusted differences (95% CI) in blood pressure, augmentation index, pulse wave velocity and asymmetric dimethylarginine concentrations between the MTX and the non-MTX group.

Variables	Model 1		Model 2		Model 3
	β (95% CI)	p-value	β (95% CI)	p-value	β (95% CI)	p-value
Clinic peripheral SBP (mmHg)	−9.0 (−14.7, −3.3)	0.002	−8.1 (−13.4, −2.8)	0.003	−7.7 (−13.2, −2.3)	0.006
Clinic peripheral DBP (mmHg)	−6.0 (−9.8, −2.3)	0.002	−5.9 (−9.5, −2.3)	0.001	−6.1 (−9.8, −2.4)	0.001
Clinic central SBP (mmHg)	−9.8 (−15.3, −4.3)	<0.001	−8.1 (−13.1, −3.0)	0.002	−7.8 (−13.1, −2.6)	0.003
Clinic central DBP (mmHg)	−5.3 (−9.0, −1.5)	0.006	−5.1 (−8.7, −1.5)	0.006	−5.4 (−9.1, −1.6)	0.005
24-hour peripheral SBP (mmHg)	−1.4 (−6.7, 3.9)	0.60	−1.1 (−6.2, 4.1)	0.69	−2.0 (−7.4, 3.3)	0.46
24-hour peripheral DBP (mmHg)	−0.4 (−3.4, 2.6)	0.81	−0.5 (−3.4, 2.5)	0.76	−1.3 (−4.4, 1.7)	0.38
24-hour central SBP (mmHg)	−3.8 (−8.3, 0.6)	0.09	−4.0 (−8.4, 0.4)	0.07	−4.2 (−8.7, 0.4)	0.07
24-hour central DBP (mmHg)	−1.9 (−4.6, 0.9)	0.18	−1.8 (−4.5, 0.9)	0.18	−1.8 (−4.5, 1.0)	0.20
Augmentation index (%)	−0.1 (−2.6, 2.4)	0.93	0.4 (−1.9, 2.7)	0.71	0.6 (−1.8, 3.0)	0.65
Pulse wave velocity (m/sec)	−0.3 (−0.9, 0.2)	0.25	−0.2 (−0.5, 0.1)	0.14	−0.2 (−0.5, 0.1)	0.12
Asymmetric dimethylarginine (µmol/l)	−0.21 (−0.47, 0.06)	0.12	−0.18 (−0.43, 0.07)	0.15	−0.19 (−0.45, 0.07)	0.15

DBP, diastolic blood pressure; MTX, methotrexate; SBP, systolic blood pressure.

Model 1: unadjusted.

Model 2: adjusted for visit, age, gender and BMI.

Model 3: adjusted for visit, age, gender, BMI and disease activity score 28.